Dutch Biotech Qiagen to Buy Digene for $1.5 Billion

Monday, 4 Jun 2007 | 8:25 AM ET

Dutch biotechnology firm Qiagen said it will acquire Digene in a transaction valued at around $1.5 billion, to create a leader in molecular diagnostics.

Qiagen, which is listed on Frankfurt's TecDAX, said the boards of directors of both companies unanimously approved the transaction in which Qiagen is to acquire 100% of Digene's stock for a combination of cash and Qiagen common stock.

It is estimated that the newly-formed company will post revenues of more than $800 million in 2008, said Qiagen in a written statement.

Qiagen CEO Peer Schatz said: "The joint franchises link virology with oncology, thereby creating an exceptional platform to add next-generation and high-value molecular diagnostic products and strategically position the company for future growth."

Schatz added that due to expected growth in the business, he did not forecast "significant changes" in the combined firm's workforce.

Copyright AFX News Limited 2007. All rights reserved.

  Price   Change %Change


Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Voice over talent Jim Birdsall, makes his CNBC television debut on "Squawk Box" and discusses his other gigs with Wal-Mart and the NFL.

  • Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Cramer reflects on his years at CNBC.

  • CNBC's Rick Santelli has the latest unemployment numbers. Lindsey Piegza, Sterne Agee and John Ryding, RDQ Economic share their thoughts on the data. Piegza says the Fed has very difficult job remaining at this accommodative pace, likely longer than expected.